Fitzgerald Kevin Joseph Insider Trading Activity

Profile

Kevin Joseph Fitzgerald is a corporate executive known for his roles in the biotechnology sector, particularly at Alnylam Pharmaceuticals and Ovid Therapeutics. He has served as Chief Scientific Officer and Executive Vice President, Head of Research at both companies, contributing to the development of RNA interference therapeutics.

Role	Insider
Notability	30/100

Board memberships

Alnylam Pharmaceuticals, Inc.
Ovid Therapeutics Inc.

Awards & honors

Leadership in RNAi therapeutics
Executive roles at Alnylam and Ovid
Contributions to drug development

Recent Transactions

Date	Ticker	Company	Code	Shares	Price	Value
2026-04-09	OVID	Ovid Therapeutics Inc.	A — Grant or award	17.6K	$2.56	$45K
2026-03-06	ALNY	ALNYLAM PHARMACEUTICALS, INC.	S — Open-market sale [10b5-1]	153	$326.24	$50K
2026-03-06	ALNY	ALNYLAM PHARMACEUTICALS, INC.	S — Open-market sale [10b5-1]	148	$324.60	$48K
2026-03-06	ALNY	ALNYLAM PHARMACEUTICALS, INC.	S — Open-market sale [10b5-1]	233	$323.25	$75K
2026-03-06	ALNY	ALNYLAM PHARMACEUTICALS, INC.	S — Open-market sale [10b5-1]	124	$321.81	$40K
2026-03-06	ALNY	ALNYLAM PHARMACEUTICALS, INC.	S — Open-market sale [10b5-1]	57	$325.67	$19K
2026-03-06	ALNY	ALNYLAM PHARMACEUTICALS, INC.	S — Open-market sale [10b5-1]	75	$324.88	$24K
2026-03-06	ALNY	ALNYLAM PHARMACEUTICALS, INC.	S — Open-market sale [10b5-1]	210	$323.84	$68K
2026-03-06	ALNY	ALNYLAM PHARMACEUTICALS, INC.	S — Open-market sale [10b5-1]	96	$323.01	$31K
2026-03-06	ALNY	ALNYLAM PHARMACEUTICALS, INC.	S — Open-market sale [10b5-1]	79	$321.82	$25K
2026-03-06	ALNY	ALNYLAM PHARMACEUTICALS, INC.	S — Open-market sale [10b5-1]	59	$320.81	$19K
2026-03-06	ALNY	ALNYLAM PHARMACEUTICALS, INC.	S — Open-market sale [10b5-1]	28	$320.01	$9K
2026-03-06	ALNY	ALNYLAM PHARMACEUTICALS, INC.	S — Open-market sale [10b5-1]	29	$319.03	$9K
2026-03-05	ALNY	ALNYLAM PHARMACEUTICALS, INC.	S — Open-market sale [10b5-1]	359	$321.58	$115K
2026-03-05	ALNY	ALNYLAM PHARMACEUTICALS, INC.	S — Open-market sale [10b5-1]	722	$320.51	$231K
2026-03-05	ALNY	ALNYLAM PHARMACEUTICALS, INC.	S — Open-market sale [10b5-1]	282	$318.62	$90K
2026-03-05	ALNY	ALNYLAM PHARMACEUTICALS, INC.	S — Open-market sale [10b5-1]	289	$316.55	$91K
2026-03-05	ALNY	ALNYLAM PHARMACEUTICALS, INC.	S — Open-market sale [10b5-1]	37	$332.64	$12K
2026-03-05	ALNY	ALNYLAM PHARMACEUTICALS, INC.	S — Open-market sale [10b5-1]	94	$331.93	$31K
2026-03-05	ALNY	ALNYLAM PHARMACEUTICALS, INC.	S — Open-market sale [10b5-1]	81	$330.85	$27K

Frequently Asked Questions

Who is Fitzgerald Kevin Joseph?

Has Fitzgerald Kevin Joseph been buying or selling stock?

Recorded transactions: 0 open-market purchases () and 57 open-market sales ($5.25M) across all tracked filings.

Where can I see all of Fitzgerald Kevin Joseph's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Fitzgerald Kevin Joseph — SEC Form 4 Insider Trading Activity

Summary